Search the Newsreel

Technical Reactions to IMCR Trends in Macro Strategies

This article analyzes Immunocore Holdings Plc (NASDAQ: IMCR) using AI models to suggest trading strategies. It highlights a strong near-term sentiment potentially challenging persistent mid and long-term weakness, identifying an exceptional short setup. The report provides specific entry, target, and stop-loss levels for position, …

IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum

Immunocore Holdings plc IMCR has gained 21.2% over the past 12 weeks, putting the durability of that advance in focus. Kimmtrak demand and late-stage pipeline progress give investors concrete operating and clinical milestones to watch. The stock's shorter-term gains have been more modest, while …

Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?

Immunocore Holdings (IMCR) presents a trade-off between its growing Kimmtrak product revenue and a premium valuation. While Kimmtrak's sales are strong and late-stage studies could expand its market, the company's reliance on a single product and higher-than-average valuation metrics pose risks. Analysts currently recommend …

Immunocore Holdings (IMCR) Posted Strong Earnings, Is The 49% Undervaluation Case Convincing?

Immunocore Holdings PLC (IMCR) Earnings Forecast: Future EPS & Revenue Growth Estimates

Immunocore Holdings plc (IMCR) Stock Price, News, Quote & History

Immunocore Holdings plc (IMCR) stock information is provided, including its current price of $34.56, up 1.71% in after-hours trading. The company, headquartered in the UK, focuses on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune conditions, with its lead product KIMMTRAK approved for …

Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues

Immunocore (IMCR) reported a Q2 2026 loss of 2 cents per share, wider than analyst estimates, despite revenues of $115.9 million, which beat expectations and increased 18.3% year-over-year. The revenue growth was primarily driven by strong sales of its drug Kimmtrak in the U.S. …

Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

Shares of Immunocore Holdings PLC Sponsored ADR (IMCR) have gained 4.3% over the past four weeks to close the last trading session at $34.5, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts …

Immunocore Holdings plc 2026: Revenue $115.93M, EPS ($0.02) — 10-Q Summary

Immunocore Holdings plc (IMCR) reported strong financial results for the quarter ended 2026, with revenue increasing to $115.93M from $97.96M year-over-year. The company significantly reduced its net loss to $808K (EPS ($0.02)) compared to a $10.3M loss (EPS ($0.2)) in the prior-year quarter. This …

How Strong H1 Profits and Kimtrak Survival Data At Immunocore (IMCR) Have Changed Its Investment Story

Immunocore Holdings plc has reported past second-quarter 2026 results showing revenue of US$115.93 million, with net loss narrowing to US$0.808 million, while first-half 2026 revenue reached US$222.60 million and shifted from a prior-period loss to net income of US$12.16 million. Alongside these figures, management …

Immunocore Holdings plc 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:IMCR) 2026-08-07

Immunocore reports second quarter financial results and provides a business update

Immunocore Holdings plc announced strong financial results for the second quarter and first half of 2026, driven by KIMMTRAK sales. The company reported $115.9 million in Q2 net revenues for KIMMTRAK, an 18% year-over-year increase, and highlighted positive five-year overall survival data for the …

How First-Half Profitability Amid a Q2 Loss at Immunocore (IMCR) Has Changed Its Investment Story

Immunocore Holdings plc reported a significant Q2 2026 revenue increase to US$115.93 million and a narrower net loss, while the first half of 2026 saw US$222.60 million in revenue and US$12.16 million in net income, marking a shift to profitability compared to the prior …

Immunocore outlines TEBE-AM data as early as end of 2026 while scaling KIMMTRAK beyond ~1,000 patients per year

Earnings Call Insights: Immunocore Holdings plc (IMCR) Q2 2026 MANAGEMENT VIEW * Dr. Bahija Jallal (CEO & Executive Director) emphasized execution against three priorities: "maximizing the value of KIMMTRAK, advancing our melanoma portfolio and expanding into other tumor types and realizing opportunities in infection …

Immunocore Holdings PLC (IMCR) (Q2 2026) Earnings Call Highlights: Strong Kimtrak Growth and ...

Immunocore Holdings PLC reported strong Q2 2026 earnings, with Kimtrak generating $223 million in net revenue in the first half of 2026, marking a 16% year-over-year growth. The company presented positive five-year overall survival data for Kimtrak in uveal melanoma and is advancing three …

Immunocore Q2 2026 slides: KIMMTRAK doubles 5-year survival rates

Immunocore Holdings reported its Q2 2026 financial results, highlighting that its therapy KIMMTRAK doubled the five-year survival rates in metastatic uveal melanoma patients. The company reported $115.9 million in revenue, an 18% year-over-year growth, and narrowed its net loss significantly. Immunocore is expanding its …

FMR LLC (IMCR) discloses 4.3M Immunocore shares under amended 13G

FMR LLC and Abigail P. Johnson have reported their beneficial ownership of Immunocore Holdings plc (IMCR) common stock via an amended Schedule 13G filing. FMR LLC beneficially owns 4,307,246 shares, representing an 8.8% stake, with sole dispositive power. Abigail P. Johnson also holds sole …

Immunocore (NASDAQ: IMCR) returns to profit as KIMMTRAK revenue climbs

Immunocore (NASDAQ: IMCR) reported a return to profit in the first half of 2026, driven by strong KIMMTRAK sales, with net revenue from therapies climbing to $222.6 million, a 16.0% increase year-over-year. The company posted a first-half net income of $12.2 million, a significant …

Earnings Flash (IMCR) Immunocore Posts Q2 Loss $0.02 a Share, vs. FactSet Est of $0.02 Loss

Immunocore Holdings plc reported a Q2 loss of $0.02 per share, which aligns with FactSet's estimate. This financial update follows an earlier report of their Q2 revenue reaching $115.9 million, surpassing FactSet's estimate of $110.4 million. The company, a United Kingdom-based biotechnology firm, specializes …

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh Revenue Breakdown – FWB:6YG

Immunocore Holdings Plc (FWB:6YG) generated €340.58 million in revenue last year, primarily from its Immunotherapies segment. The United States was the largest geographical contributor, accounting for €218.81 million of the company's revenue. The article highlights the company's top-performing segment and its major market.

Immunocore set to report earnings ahead of pivotal trial data

Immunocore Holdings PLC is set to report second-quarter financial results with investors focusing on the commercial performance of its drug KIMMTRAK and the progress of its clinical trial for cutaneous melanoma. Analysts anticipate earnings of $0.01 per share on $110.3 million in revenue. The …

Immunocore Q2 2026 Earnings Preview

* Immunocore (IMCR [https://seekingalpha.com/symbol/IMCR]) is scheduled to announce Q2 earnings results on Thursday, August 6th, before market open. * The consensus EPS Estimate is $0.02 [https://seekingalpha.com/symbol/IMCR/earnings/estimates] (+110.0% Y/Y) and the consensus Revenue Estimate is $110.37M (+12.6% Y/Y). * Over the last 3 months, EPS …

Immunocore Holdings PLC Sponsored ADR $IMCR Position Boosted by Janus Henderson Group PLC

Janus Henderson Group PLC increased its stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 30.9% in the first quarter, now owning 594,712 shares worth $17.9 million. Several other institutional investors also adjusted their positions, with institutional investors and hedge funds collectively owning 84.5% …

ETFs Investing in Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh Stocks

This article lists various ETFs that include Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh stocks in their portfolios. The funds are sorted by market value and provide key financial metrics such as weight, issuer, management style, expense ratio, AUM, price, …

Mizuho Lifts Price Target on Immunocore Holdings to $35 From $34, Keeps Neutral Rating

Mizuho has increased its price target for Immunocore Holdings (IMCR) to $35 from $34, while maintaining a Neutral rating on the stock. This adjustment reflects a modest positive outlook from the firm regarding the biopharmaceutical company's valuation.

Trading the Move, Not the Narrative: (IMCR) Edition

This article analyzes Immunocore Holdings Plc (NASDAQ: IMCR), highlighting a near-term weak sentiment that could test mid-term strength within a broader long-term weak bias. It identifies a mid-channel oscillation pattern and offers three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different …

Immunocore to Detail Its Business and Portfolio on Aug. 6

Immunocore (NASDAQ: IMCR) will release its second-quarter 2026 financial results on Thursday, August 6, 2026, for the period ending June 30, 2026. The company will host a live teleconference and webcast at 8:00 a.m. EDT to discuss the results and provide updates on its …

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026

Immunocore Holdings plc (Nasdaq: IMCR) announced it will report its financial results for the second quarter ended June 30, 2026, on Thursday, August 6, 2026. Following the announcement, the company will host a live teleconference and webcast at 8:00 AM ET to discuss these …

Immunocore Holdings PLC (IMCR) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Immunocore Holdings PLC (IMCR), noting its current valuation score of 9.63, ranking 13th in the Pharmaceuticals industry. The company's P/E ratio is -60.75, which is significantly below its recent high and above its recent low. Key valuation …

Immunocore (IMCR) Projected to Release Quarterly Earnings on Thursday

Immunocore Holdings PLC (IMCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Immunocore Holdings PLC (IMCR), focusing on its support and resistance levels, various technical indicators, and moving averages. As of July 28, 2026, IMCR's price momentum score is 3.98, and the stock is trading between a resistance of …

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh Revenue Breakdown – MUN:6YG

This article provides a revenue breakdown for Immunocore Holdings Plc (MUN:6YG). Last year, the company generated €340.58 million, with the Immunotherapies segment contributing the entire amount. The United States was the primary geographic contributor, accounting for €218.81 million of the total revenue.

How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak

Immunocore Holdings is strategically shifting its focus beyond its single rare-cancer drug, Kimmtrak, leveraging its T-cell receptor platform into broader markets. This expansion includes testing its technology in various solid tumor indications, infectious diseases, and autoimmune conditions. While Kimmtrak remains a commercial success, the …